Skip to Content

Keratoconus: Why the Cornea Bulges, How It's Caught Early & Treated (Cross-Linking to Transplant) 2026

Keratoconus Explained: Symptoms, Cross-Linking & Transplant Guide 2026 | Agaaz Ophthalmics

Intraocular Solutions · Science Series

Why does the cornea
start to bulge?
The science of keratoconus.

A complete guide to keratoconus — the progressive corneal thinning disorder that quietly worsens for years before it's caught. Warning signs, topography diagnosis, and the treatment ladder from cross-linking to transplant.

90%

progression halted
by early cross-linking

1 in 5

diagnosed cases
eventually need transplant

10-20

years typical
progression window

14 min

reading time

Section 01 — Definition

What is keratoconus?
A cornea that loses its shape.

Every year, a wave of teenagers and young adults are told their eyes "just keep changing" and are handed a stronger glasses prescription. In a subset of them, the real problem isn't the prescription — it's the shape of the cornea itself, slowly warping underneath a lens that can never fully compensate.

Keratoconus is a progressive structural disease. The collagen fibrils that normally hold the cornea in a smooth, symmetric dome weaken in a localised zone — usually just below the visual axis. Under ordinary intraocular pressure, that weakened zone can no longer hold its shape and bulges outward into an irregular cone. Light entering the eye scatters instead of focusing to a single point, producing blur that no ordinary spherical or cylindrical lens can fully correct.

The biochemistry, in 140 words

Corneal collagen fibrils are normally cross-linked to each other like scaffolding, giving the tissue the rigidity to hold a precise dome shape. In keratoconus, that cross-linking is biochemically weaker than normal: enzymes that break down collagen (matrix metalloproteinases) become overactive, while the natural inhibitors that should hold them in check are underactive. The net effect is a cornea that slowly loses structural integrity in one zone. Chronic eye rubbing is the strongest identified modifiable risk factor — mechanical stress repeatedly applied to an already-weakened zone accelerates the bulge. Family history, allergic eye disease, Down syndrome, and connective tissue disorders (Ehlers-Danlos, Marfan) all raise risk. It is usually bilateral but asymmetric — one eye often noticeably worse at diagnosis. Sources: Rabinowitz YS, Surv Ophthalmol 1998; Gomes JAP et al., Cornea 2015.

Fast-changing prescription
Needing a new glasses prescription every few months, especially in one eye, when most people's prescriptions stay stable for years at a time.
Ghosting & streaking
A faint duplicate or "streak" version of letters and lights that glasses reduce but never fully clear — irregular astigmatism glasses can't correct.
Glare & halos at night
Headlights and streetlights bloom into starbursts or halos, often more pronounced than typical age-related night-vision complaints.
Chronic eye rubbing
A personal history of persistent itching and rubbing, often with a background of allergic conjunctivitis — the single strongest modifiable risk factor.

Section 02 — Diagnosis

How it's actually diagnosed
and staged.

Standard vision testing and even standard autorefraction can miss early keratoconus entirely — the eye can still resolve reasonable acuity with the right lens combination even as the cornea quietly warps underneath. The tool that catches it is corneal topography.

Corneal topography: mapping the warp

Topography (and its more detailed cousin, tomography) scans the curvature of the entire corneal surface in thousands of points and renders it as a colour map. A normal cornea shows smooth, symmetric, gently-graded curvature. A keratoconic cornea shows a localised hot zone of steep curvature, usually inferior or inferotemporal to the visual axis, standing out clearly against the surrounding normal tissue. Repeated scans months apart are how progression — not just diagnosis — is tracked, and progression is what actually determines whether cross-linking is recommended.

Interactive Keratoconus Stage Simulator
Select a stage to see how the corneal cross-section profile steepens and thins over time. Illustrative schematic only.
Normal corneal profile Cone / steepened zone Thinning gradient

Staging: how far has it progressed

StageFindingsTypical Approach
I — MildSubtle topographic irregularity, glasses still correct vision reasonably well, corneal thickness near normalMonitor; cross-linking if progression confirmed
II — ModerateVisible steepening and thinning, glasses correction degrades, mild irregular astigmatism on examCross-linking strongly indicated
III — AdvancedMarked cone, corneal thinning obviousRigid or scleral contact lenses; cross-linking if still progressing
IV — SevereSignificant scarring risk, very steep and thin cornea, contact lens fitting becomes difficultTransplant evaluation (DALK or PK)

Staging commonly follows the Amsler-Krumeich classification.

Section 03 — Treatment Ladder

The treatment ladder:
from cross-linking to transplant.

Three distinct interventions exist, and matching the right one to the right stage is the entire discipline of keratoconus management.

GoalStop progression — the only treatment shown to halt the disease rather than just compensate for it
HowRiboflavin (vitamin B2) drops saturate the cornea, then are activated with a controlled dose of UV-A light, forming new covalent bonds between collagen fibrils
EvidenceProgression halted in ~90% of treated eyes in long-term studies; some show modest topographic flattening over 1-2 years
Best candidateYounger patient with a documented progressing cornea, Stage I-II — catching it early is the entire point
LimitationDoes not restore vision already lost to scarring or irregularity — it protects what shape remains
GoalRestore functional vision once the cornea is too irregular for ordinary soft lenses to correct
RGP lensesRigid gas-permeable lenses hold a precise, regular optical surface in front of the eye, with a tear layer filling the gap beneath
Scleral lensesLarger-diameter rigid lenses that vault over the entire cornea and rest on the sclera — the modern standard for moderate-to-advanced disease; more comfortable, mask more irregularity
Best candidateStage II-III, stable or post-cross-linking, where soft lenses/glasses no longer give functional vision
GoalReplace diseased tissue when the cornea has scarred, thinned to a risk point, or steepened beyond what any lens can fit
DALKDeep anterior lamellar keratoplasty — replaces only the diseased outer layers, preserving the patient's own healthy endothelium, lower rejection risk
Penetrating (PK)Full-thickness transplant, used for advanced scarring involving deeper corneal layers
Best candidateStage IV, or any stage with significant central scarring from an episode of acute corneal swelling (hydrops)
More detailSee our companion guide on corneal transplant surgery and donation in India
The one habit that actually matters: Of every modifiable risk factor identified for keratoconus, chronic eye rubbing has the strongest and most consistent evidence behind it. If allergic conjunctivitis or itching is the reason someone rubs, treating the underlying allergy — antihistamine drops, avoiding the trigger, cold compresses instead of rubbing — is one of the simplest interventions that measurably protects the cornea, and it costs nothing.

Section 04 — Clinical Evidence

Treatment outcomes:
the evidence.

Published long-term data on how each intervention actually performs, aggregated from peer-reviewed follow-up studies.

CXL progression halted at 5+ years~90%
Functional vision achieved with RGP/scleral lens~85-95%
Diagnosed cases eventually needing transplant10-20%
CXL eyes needing a repeat treatment (10yr)5-10%
Why early catch matters: Cross-linking only protects the shape a cornea still has — it cannot restore shape already lost. A patient diagnosed at Stage I who gets CXL promptly has a very different long-term trajectory than one diagnosed at Stage III after years of "just needs a stronger prescription."

Section 05 — Surgical Support

What keeps a transplant
surgery safe.

When keratoconus reaches transplant stage, outcome depends on more than the donor tissue — the surgical consumables used during the procedure protect the delicate anterior chamber and corneal endothelium throughout.

Trypan Blue Ophthalmic Solution
Vital Corneal & Capsular Stain
Used in DALK to stain and visualise the depth of the diseased stroma being dissected, and in any concurrent cataract step to stain the anterior capsule for clear visualisation. See our dedicated guide on Trypan Blue uses and safety.
PURE-HYAL / PURE-VISC
Ophthalmic Viscosurgical Devices
Sodium hyaluronate OVDs maintain anterior chamber depth and protect the corneal endothelium during graft suturing and any combined intraocular work — a core part of Agaaz's complete surgical intraocular solutions package.

Our portfolio also includes OP-BLADE precision microsurgical knives and MOXGUARD intracameral moxifloxacin for endophthalmitis prophylaxis. View the complete Agaaz product portfolio →

Section 06 — FAQ

Frequently asked questions
about keratoconus.

The earliest sign is usually a fast-changing eyeglass prescription in one eye, blurred or ghosted/doubled vision that glasses cannot fully correct, and increasing sensitivity to glare or halos around lights at night. It typically starts in the teens to early twenties and progresses over 10-20 years.

There is no cure that reverses the corneal shape, but corneal collagen cross-linking (CXL) halts progression in roughly 90% of eyes when done early, and most people manage vision long-term with rigid or scleral contact lenses. Only advanced, scarred corneas need a transplant.

Cross-linking is done under topical anaesthetic drops; patients feel pressure but not pain during the roughly 30-60 minute procedure, though the eye is gritty and light-sensitive for 3-5 days after as the surface heals.

Transplant is reserved for advanced keratoconus where the cornea has scarred, become too thin or steep for a contact lens to fit, or vision can no longer be corrected to a functional level with lenses — roughly 10-20% of diagnosed cases eventually need one.

Cross-linking stiffens the treated tissue permanently, but a minority of eyes (estimates range 5-10%) show continued flattening loss over many years and may need a repeat treatment; annual topography monitoring catches this early.

References & Evidence Base

Peer-reviewed
citations.

Rabinowitz YS. "Keratoconus." Surv Ophthalmol. 1998;42(4):297-319.
Gomes JAP, et al. "Global consensus on keratoconus and ectatic diseases." Cornea. 2015;34(4):359-69.
Wollensak G, Spoerl E, Seiler T. "Riboflavin/ultraviolet-A-induced collagen crosslinking for the treatment of keratoconus." Am J Ophthalmol. 2003;135(5):620-7.
Raiskup-Wolf F, et al. "Collagen crosslinking with riboflavin and UV-A light in keratoconus: long-term results." J Cataract Refract Surg. 2008;34(5):796-801.
Sarezky D, et al. "Trends in Corneal Transplantation in Keratoconus." Cornea. 2017;36(2):131-137.
McMonnies CW. "Mechanisms of rubbing-related corneal trauma in keratoconus." Cornea. 2009;28(6):607-15.

Continue Reading